Status:

TERMINATED

Targeting Leukotrienes in Kidney Disease

Lead Sponsor:

University of Colorado, Denver

Conditions:

Diabetic Kidney Disease

Eligibility:

All Genders

30-70 years

Phase:

PHASE3

Brief Summary

Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inf...

Eligibility Criteria

Inclusion

  • CKD stage 3
  • urine albumin to creatinine ratio 200-5000 mg/g
  • blood pressure \<140/90 mmHg
  • use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks
  • history of diabetes type 1 or 2
  • BMI \<40 kg/m2
  • Stable antihypertensive regimen for at least one month prior to enrollment
  • Stable diabetes regimen for at least one month prior to enrollment
  • Sedentary or recreationally active (\<2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements)
  • Able to provide consent

Exclusion

  • Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year
  • Uncontrolled hypertension
  • Factors judged to limit adherence to interventions (e.g. history of medication noncompliance, noncompliance with follow up visits, significant cognitive impairment, etc.)
  • Anticipated initiation of dialysis or kidney transplantation within 3 months
  • Current participation in another research study
  • Pregnancy or planning to become pregnant or currently breastfeeding
  • Allergy to aspirin
  • Severe hepatic impairment (Child-Pugh Class C)
  • History of major psychiatric disorder
  • Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction)
  • Current use of SGLT2 inhibitor
  • Current use of phenobarbital, rifampin or carbamazepine.

Key Trial Info

Start Date :

July 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 20 2023

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT05362474

Start Date

July 1 2022

End Date

June 20 2023

Last Update

May 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado

Aurora, Colorado, United States, 80045